Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications
Advanced Drug Delivery Reviews · 2024
DOI: 10.1016/j.addr.2024.115303 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2024. Verfasst von Jacob D Bonadio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Temple University, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Fibronectins, Fibrosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 250 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Temple University, W W Smith Charitable Trust.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Temple University, Philadelphia, PA, United States.
- Department of Bioengineering, Temple University, Philadelphia, PA, United States. Electronic address: karin.wang@temple.edu.
Förderung
- NIGMS NIH HHS
- Temple University
- W W Smith Charitable Trust
- National Institutes of Health
Zitieren
APA
Bonadio, J. D., Bashiri, G., Halligan, P., Kegel, M., Ahmed, F., & Wang, K. (2024). Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2024.115303
Vancouver
Bonadio JD, Bashiri G, Halligan P, Kegel M, Ahmed F, Wang K. Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications. Advanced Drug Delivery Reviews. 2024. doi:10.1016/j.addr.2024.115303
BibTeX
@article{Bonadio2024,
author = {Bonadio, Jacob D and Bashiri, Ghazal and Halligan, Patrick and Kegel, Michael and Ahmed, Fatima and Wang, Karin},
title = {Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications},
journal = {Advanced Drug Delivery Reviews},
year = {2024},
doi = {10.1016/j.addr.2024.115303}
}
EUVIMED